Regenerex Pharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Regenerex Pharma, Inc. reported a reduced net loss for the fiscal year ended March 31, 2025, driven by decreased research and development expenses, while actively pursuing significant strategic partnerships and additional capital to address ongoing liquidity challenges and a going concern doubt.
Regenerex Pharma, a wound care company, reported its full year 2024 results, highlighting a significant net loss and ongoing efforts to launch its wound care products.